Psilocybin-Assisted Therapy Achieves 75% Response Rate in Treatment-Resistant IBS Patients
核心洞察
Entropy Neurodynamics (搜索) reported breakthrough Phase 2a results showing 75% of treatment-resistant IBS (搜索) patients achieved clinically meaningful improvements with oral psilocybin plus structured psychotherapy.
The response rate significantly exceeded the 17-44% typically observed with approved IBS (搜索) therapies, with IBS-C subtype showing 100% response rate.
Study findings demonstrated strong correlation between symptom improvements and psychological mechanisms, supporting gut-brain axis (搜索) targeting rather than symptom masking.
Entropy Neurodynamics (搜索) has announced breakthrough results from a Phase 2a study of TRP-8802, demonstrating that psilocybin-assisted therapy achieved a 75% response rate in patients with treatment-resistant irritable bowel syndrome (搜索) (IBS (搜索)). The open-label pilot study, presented at Digestive Disease Week 2026 by teams from Massachusetts General Hospital and Columbia University, represents a significant advance for one of the most difficult-to-treat chronic conditions.
Study Design and Patient Population
The trial enrolled 12 patients who had previously failed multiple standard treatments, evaluating two doses of oral psilocybin administered with structured psychotherapy. All participants met a predefined clinical response threshold on the IBS (搜索) Symptom Severity Score, providing compelling evidence for the therapy's efficacy in a treatment-resistant population.
Superior Response Rates Across IBS Subtypes
The 75% overall response rate substantially exceeded the 17% to 44% response rates typically observed with approved IBS (搜索) therapies, where treatment failure and relapse are common. Subgroup analysis revealed particularly strong outcomes, with IBS-C (constipation-predominant) showing a 100% response rate, IBS-M (mixed) achieving 80%, and IBS-D (diarrhea-predominant) reaching 50%.
"To deliver a 75% response rate in a treatment-resistant population, where existing therapies typically achieve only modest outcomes, is clinically unprecedented," said CEO Jason Carroll, calling the results a "breakthrough moment for Entropy and for the treatment of IBS (搜索)."
Mechanistic Validation Through Gut-Brain Axis
The study provided crucial mechanistic insights, demonstrating strong correlations between symptom improvements and psychological mechanisms. Investigators found that reductions in psychological inflexibility and gains in psychological insight correlated with clinical benefit, while gut-specific anxiety showed minimal change. This pattern supports a gut-brain axis (搜索) mechanism acting on central brain pathways rather than simply masking peripheral symptoms.
"We are seeing clear alignment between clinical outcomes and improvements in psychological drivers—reinforcing that we are targeting the root cause of disease through the gut-brain axis (搜索)," Carroll explained. The mechanistic coherence confirmed that the therapy was engaging the gut-brain axis, which is a core driver of IBS (搜索), aligning with Entropy's mechanism-based development strategy.
Safety Profile and Clinical Management
One serious adverse event was recorded and resolved with appropriate clinical support, underscoring the importance of standard psychological screening and integration procedures. The safety data supports the feasibility of psychedelic-assisted therapy in this patient population when proper clinical protocols are followed.
Development of Next-Generation TRP-8803
The TRP-8802 program was specifically designed to inform the development of TRP-8803, Entropy's proprietary intravenous psilocin formulation. TRP-8803 offers several advantages over oral psilocybin, including faster onset of action and precise control over dose, depth, and duration of therapeutic effect. This provides both an improved patient and therapist experience and a more commercially scalable treatment model.
The Phase 2a trial provided direct mechanistic validation for TRP-8803's use in IBS (搜索) treatment, significantly enhancing its commercial and partnering profile. Entropy expects the mechanistic coherence to significantly de-risk its drug development program and support progression to larger controlled studies.
Market Opportunity and Future Development
IBS (搜索) is a chronic gut-brain disorder characterized by pain, bloating, constipation, diarrhea, urgency, and impaired quality of life. The condition affects 10.4 million people in the US and over 1 million in Australia, with high unmet need in treatment-resistant populations. IBS patients commonly cycle through up to 10 therapies, demonstrating strong willingness to adopt new treatments despite substantial out-of-pocket costs.
Entropy is continuing to review its IBS (搜索) dataset as it commences planning for new US-based clinical trials and pursues non-dilutive grant funding to advance trials using TRP-8803. The company believes TRP-8803 has the potential to deliver a best-in-class therapeutic profile in the multi-billion dollar global IBS market, with larger, controlled, and subtype-stratified trials needed to confirm durability, safety, and effect size.